臨床試験における多様な患者集団を確保するための実践的な戦略

臨床試験はますます複雑になっています。 各研究で使用されるエンドポイント、手順、およびサイトの数がすべて増加しました。 これにより、患者の募集、特に多様な患者の募集がより困難になります。

ホワイトペーパーをダウンロードして、さらに詳しく知りましょう。

PDF preview of White Paper available for download.
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.



究極の目標は、誰もが教育の有無、肌の色、年齢、民族、社会経済的地位、地理的位置に関係なく、特定の薬に同じレベルでアクセスできるような、より良い健康の公平性を持つ世界です。
Claire Riches, Head of Clinical Solutions, Citeline

Related resources

''
SEP 20, 2024
Infographic
薬事規制関連支援サービス

What US FDA Is Expecting and When

See what the US FDA is expecting from diversity action plans and when this might be implemented.

A female scientist in a lab coat holds a tube, conducting experiments in a laboratory setting.
MAY 07, 2024
Article
Clinical

Diversity at the Start: Best Practices for Clinical Trial Planning

Study sponsors should begin their clinical trial diversity efforts with a fit-for-purpose clinical protocol.

Man exploring options for a diverse clinical trial.
MAY 29, 2024
Article
Clinical

Practical Approaches to Clinical Trial Diversity

Learn best practices in increasing diversity in clinical trials. Experts from GSK, Pfizer, AbbVie, and Bristol Myers Squibb discuss their multipronged approaches.